First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis

First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis

Abstract The Phase 3 RATIONALE-312 trial (NCT04005716) showed that tislelizumab plus chemotherapy led to a noteworthy enhancement resulted in a significant improvement in overall survival among patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) compared to chemotherapy alone. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong Long, Fangping Chen
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
Extensive-stage small-cell lung cancer (ES-SCLC)
Markov model
Cost-effectiveness
Quality-Adjusted life years (QALYs)
Tislelizumab
First-line
Online Access:https://doi.org/10.1038/s41598-024-83509-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-83509-x

Similar Items